Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating activities
Net loss	$ (4,404,770)	$ (2,447,320)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	8,340	4,323
Stock-based compensation	1,533,888	82,772
Restricted stock issued for services	64,000	0
Change in fair value of warrants	0	(19,807)
Debt discount amortization	71,547	0
Increase (decrease) in operating assets and liabilities:
Grant receivable	483,924	(155,195)
Other receivables	0	2,275
Prepaid expenses and other	69,650	44,474
Accounts payable	(1,060,796)	753,184
Accrued clinical operations and site costs	81,949	22,847
Accrued compensation	(98,927)	88,434
Other accrued expenses	339,565	200,483
Net cash used in operating activities	(2,911,630)	(1,423,530)
Investing activities
Purchases of property and equipment	(153,899)	(28,867)
Net cash used in investing activities	(153,899)	(28,867)
Financing activities
Cash received from bank loan, net of financing costs	4,610,324	0
Issuances of common stock, net of issuance costs	0	4,714,726
Net cash provided by financing activities	4,610,324	4,714,726
Net change in cash and cash equivalents	1,544,795	3,262,329
Cash and cash equivalents at beginning of period	4,084,085	1,477,143
Cash and cash equivalents at end of period	5,628,880	4,739,472
Supplemental disclosures of non-cash investing and financing information:
Capital lease in connection with purchases of equipment	95,656	0
Purchase of equipment in accounts payable	109,471	0
Deemed dividend on beneficial conversion feature for preferred stock	0	17,852,921
Accretion of redemption value for Series A-1 and B preferred stock	0	93,234
Conversion of Series A-1 redeemable preferred stock into common stock	0	162,968
Conversion of Series C preferred stock to common stock	0	966
Conversion of Series B preferred stock to common stock	0	160,380
Exchange of Series A-1 preferred stock and warrants into common stock and Series D preferred stock	0	13,111,280
Exchange of Series B preferred stock and warrants into common stock and Series D preferred stock	0	10,451,784
Fair value of warrants issued	$ 607,338	$ 0